 An analysis of 65,061 globally recruiting clinical trials across 186 countries finds that 4,361 studies, equivalent to 6.7% of all active trials, are impacted by disruption in the Middle East. The research, conducted by data analytics firm Phesi, found that across a total of 356,699 recruiting investigator sites, 7,958, or 2.2%, are in the affected region, with Phase III trials accounting for the highest number of impacted sites at 2,732. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
